News By Tag
* More Tags...
News By Location
Cambridge-based biotech Isogenica announces new partnership with Phylogica
Isogenica and Phylogica target peptide drugs for inflammatory disease
Having already demonstrated lead peptide compounds that bind with high affinity and are biologically active against CD40L, Phylogica (http://www.phylogica.com) will utilise Isogenica’s CIS display technology to initiate a comprehensive search process to optimize the exact chemical and three dimensional structure required to further enhance the properties of the Phylomer peptides. Helping improve drug properties such as affinity, stability and potency.
“We believe that the use of CIS display will accelerate the rapid entry of Phylogica drug candidates into preclinical development programmes and increase their commercial value”, said Professor Paul Watt, Phylogica’s VP, Corporate Development. “Phylomers are sourced from the most structurally diverse peptide libraries in the world which translates into exceptionally high bioactive hit rates, including primary hits with picomolar affinities for their targets”, Prof Watt added.
Kevin Matthews, CEO of Isogenica commented of the partnership:
Phylogica joins over a dozen leading pharmaceutical and biotech companies that have already partnered with Isogenica in the discovery of novel peptides for therapeutic and non-therapeutic applications or for licenses. These include Amgen, AstraZeneca, Centocor, GE Healthcare, Invitrogen, Johnson & Johnson, Pfizer, Smiths Detection Systems, UCB, Wyeth.
# # #
About Isogenica: Isogenica specialises in providing protein engineering services using its core technology, “CIS display”, to pharmaceutical and biotechnology companies for the discovery, identification and design of new peptide, polypeptide and antibody lead compounds.
CIS display can construct within a few hours polypeptide libraries of unprecedented size and complexity in vitro, without the need for cloning. These can be processed to identify better products and motifs in just a few days. Active peptides with antibody-like levels of affinity and specificity for target compounds can be isolated and then rapidly matured to optimise desirable qualities. CIS display technology has particular benefits against biological membrane preparations, cells and bacteria. The technology is adaptable for the display of different proteins and has been licensed for the Centyrin scaffold. http://www.isogenica.com